Baseline OCT Biomarkers Associated with the 2-year Development of Macular Atrophy or Fibrosis in Neovascular AMD

Purpose: To evaluate baseline structural OCT biomarkers associated with the development of macular atrophy or fibrosis in treatment-naïve eyes with exudative neovascular age-related macular degeneration (AMD) managed with a treat-and-extend (T 95% CI, 2.23-16.48)and type 3 MNV (HR, 4.38; 95% CI, 1.63-11.73)as independent predictors of macular atrophy, whereas type 1 MNV was protective J o u r n a l P r e -p r o o f OCT biomarkers of macular complications in neovascular AMD (HR, 0.23; 95% CI, 0.09-0.61).Type 2 MNV emerged as the strongest predictor of macular fibrosis (HR, 7.28; 95% CI, 1.51-35.10).Conclusions: Baseline OCT biomarkers, particularly IRF and type 3 MNV, strongly predict macular atrophy, while type 2 MNV predicts fibrosis in eyes with exudative neovascular AMD treated with a T&E regimen.Type 1 MNV may confer protection against atrophy.These exploratory findings underscore the value of comprehensive baseline OCT assessment for anticipating long-term structural outcomes and guiding clinical management.